-
Featured
Innovations in ALS Clinical Trials
Merit Cudkowicz, MD, MSc, chief of Neurology at Massachusetts General Hospital, discusses innovations in ALS clinical trials since she started in the field in 1994.
-
Featured
Advancements in the Treatment of Neurodegenerative Disease
In this video, Ghazaleh Sadri-Vakili, PhD, director of the NeuroEpigenetics Laboratory and the MassGeneral Institute of Neurodegenerative Disease, discusses her genetic research, specifically concerning neurodegenerative diseases like ALS and X-linked dystonia parkinsonism.
-
Featured
Identifying New Potential Therapeutic Targets for ALS FTD
Transcripts of repeat expansions in the C90RF72 gene undergo a repeat-associated non-AUG (RAN) translation pathway that generates multiple aberrant proteins. Researchers at Mass General Hospital identified new potential therapeutic targets for ALS FTD.
-
Healey Center Speeds ALS Research for Patient Therapies
The Healey Center at Massachusetts General Hospital is a worldwide leader in ALS research that speeds new therapies to patients.
-
Researchers Identify a New Therapeutic Target for TDP-43-mediated Neurodegenerative Diseases
Loss of TDP-43 nuclear function is a major event in ALS pathogenesis and leads to widespread RNA processing alterations including reduced stathmin-2 levels. Stathmin-2 is shown to be crucial for axonal regeneration and to represent a novel therapeutic target in ALS.
-
Nuclear-import Receptors Can Dissolve Cytoplasmic Protein Aggregates Associated with Neurodegenerative Disorders Such as ALS
Massachusetts General Hospital investigators assessed the role of nuclear import receptor (NIRs) in disrupting such aggregates associated with neurodegenerative disorders, chaperoning these proteins from the cytoplasm to the nucleus and restoring their normal function, thereby rescuing the cell from degeneration.
Learn about the Sean M. Healey & AMG Center for ALS at Mass General
ALS contributors
-
Clotilde Lagier-Torurenne, MD, PhD
Assistant Professor of Neurology, Harvard Medical School, Assistant in Neuroscience, Massachusetts General Hospital
Recent Article
Researchers Identify a New Therapeutic Target for TDP-43-mediated Neurodegenerative Diseases
-
Ghazaleh Sadri-Vakili, MS, PhD
Assistant in Neuroscience, Massachusetts General Hospital, Assistant Professor of Neurology, Harvard Medical School
Recent Article
Research Advances from Mass General Neurology
-
James D. Berry, MD, MPH
Co-director, Multidisciplinary Amyotrophic Lateral Sclerosis (ALS) Clinic
Recent Article
Infusions of Regulatory T Cells Slowed ALS Progression in First-in-Humans Trial
-
Merit Ester Cudkowicz, MD, MSc
Chief, Neurology Service, Director of the Sean M. Healey & AMG Center for ALS at Mass General, Director of Neurological Clinical Research Institute and the Jilieane Dorn Professor of Neurology, Harvard Medical School
Recent Article
Healey Center Speeds ALS Research for Patient Therapies
-
Nazem Atassi, MD
Associate Director, Neurological Clinical Research Institute (NCRI), Mass General Hospital, Associate Professor of Neurology, Harvard Medical School
Recent Article
Novel Immunomodulator Safe and Tolerable in Pilot Study for ALS
Neuroscience Care at Mass General
Through a combination of unmatched expertise, creativity and compassion, Mass General Neuroscience relentlessly advances the fields of Neurosurgery, Neurology and Psychiatry to unleash our patients’ potential.Resource Links
